Medical University of South Carolina

MEDICA
Pharmacy & Therapeutics Update: Drug Information for Health Care Professionals
5-1-2007

Pharmacy & Therapeutics Update: Drug Information for Health
Care Professionals, April/May 2007
Medical University of South Carolina
Paul W. Bush
Medical University of South Carolina

Kelli L. Garrison
Medical University of South Carolina

Jason Cooper
Medical University of South Carolina

Follow this and additional works at: https://medica-musc.researchcommons.org/musc-ptupdate

Recommended Citation
Medical University of South Carolina; Bush, Paul W.; Garrison, Kelli L.; and Cooper, Jason, "Pharmacy &
Therapeutics Update: Drug Information for Health Care Professionals, April/May 2007" (2007). Pharmacy
& Therapeutics Update: Drug Information for Health Care Professionals. 14.
https://medica-musc.researchcommons.org/musc-ptupdate/14

This Newsletter is brought to you for free and open access by MEDICA. It has been accepted for inclusion in
Pharmacy & Therapeutics Update: Drug Information for Health Care Professionals by an authorized administrator
of MEDICA. For more information, please contact medica@musc.edu.

Pharmacy & Therapeutics

Update
Drug Information for
Health Care Professionals
Drug Information Center
Medical University of South Carolina
Department of Pharmacy Services
Charleston, South Carolina

Visit us on the Web!
www.formularyproductions.com/musc

Editorial Staff
Paul W. Bush, PharmD, FASHP
Director, Department of Pharmacy
Services

Kelli L. Garrison, PharmD, BCPS
Manager, Medication Use Policy and
Informatics
Editor; Newsletter Layout

Jason Cooper, PharmD
Drug Information Specialist
Associate Editor

In This Issue
▪ CMS Quality Initiatives Series
Part II: Heart Failure
▪ Did You Know… Market
Removals for Pergolide,
Tegaserod, and
Trimethobenzamide
▪ MED•U•WAY Program to
Focus on eCareNet, the
MUSC Clinical Record
▪ Bioequivalence and Pharmaceutical Equivalence of
Generic Drugs
▪ Formulary Updates for
April and May 2007

April/May 2007

CMS Quality Indicator Initiatives Series
Part II: Heart Failure
By: Kim Blanco, PharmD
Pharmacy Practice Resident
Health care is always a top priority in this country and often the
topic of discussion and debate.
In 2004, Medicare spent $300
billion on health care costs, making it the largest purchaser of
healthcare in the nation.1
In an effort to improve the quality of health care and decrease
costs, the Department of Health
and Human Services (HHS) and
the Centers for Medicare and
Medicaid Services (CMS) have
joined to create a program called
the Quality Initiative. The purpose of the Initiative is to encourage health care providers to
enhance the quality of care by
providing financial incentive and
to empower consumers with
quality of care information to
make more informed decisions
about their health care.
The details regarding the initiative are described in the March
2007 issue (www.musc.edu/
pharmacyservices/PnT/
Mar07.pdf).
This month the focus will be on
the heart failure initiative. Table
1 outlines the 4 specific meas-

ures, which includes assessment
of left ventricular function (LVF),
prescribing of angiotensin converting enzyme inhibitor (ACEI)
or angiotensin receptor blocker
(ARB) for left ventricular function
systolic dysfunction (LVSD),
comprehensive discharge instructions, and smoking cessation advice and counseling.2,3 LVSD is
defined as documentation of left
ventricular ejection fraction of
less than 40% or a narrative description of left ventricular function.2 These measures are consistent with the guidelines set forth
by the American College of Cardiology/American Heart Association Task Force.4
Appropriate selection of medications to reduce morbidity and
mortality in heart failure requires
the identification of patients with
impaired left ventricular systolic
function. National guidelines advocate the evaluation of LVSD
function as the single most important diagnostic test in the management of all patients with heart failure.3,4
ACEI therapy has been shown to
reduce mortality and morbidity in
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patients with heart failure and
LVSD. Recent clinical trials have
also established ARB therapy as
an acceptable alternative to ACEI,
especially in patients who are
ACEI intolerant. National guidelines strongly recommend ACEIs
for patients hospitalized with heart
failure.3,4 Additionally, guideline
committees have supported the
inclusion of ARBs in performance
measures for heart failure.3

patients with heart failure.3 To
remain compliant with the measures, it is important that each
measure is properly documented
in the patient’s medical record.
Several preprinted order forms
and discharge forms are available to provide appropriate
places for documentation. These
forms are located on the Clinician Order Forms Web page on
the MUSC Intranet (Table 2).

Providing comprehensive discharge instructions is emphasized
since patient non-compliance with
diet and medications can lead to
changes in clinical status.3 Smoking cessation reduces mortality
and morbidity in all populations.
It has been shown that patients are
more likely to stop smoking if
they receive even brief smokingcessation advice from their care
providers.4

Once submitted, the data are accessible online to consumers
through the HHS Hospital Comp a r e
W e b
s i t e
( www.hospitalcompare.hhs.gov ).
The rates of compliance with
each measure are available for
MUSC, other local hospitals, as
well as for state and national averages. The Outcomes and Quality Management division collects
data on all patients who were
discharged with a primary diagnosis of heart failure. The data
regarding performance with the
specific measures are entered

Despite the national recommendations, these measures are missed
or rarely provided in eligible older

into a database and submitted to
CMS. Currently, data are available for discharges during the
months of January through June
2006 and July through September
2006 (Table 1).
The individual measures for the
clinical areas offer hospitals specific goals that can be used to improve patient care in those disease
states. As part of the MUSC Excellence campaign, the organization has established a goal of at
least 95% compliance with all
CMS quality measures; therefore,
is it critical that every health care
professional is aware of the CMS
Initiative, how the organization is
performing, and where we need to
focus our efforts.
In 2 of the 4 heart failure measures, the organizational goal of at
least 95% has been reached (Table
1). Additionally, MUSC exceeds
the national average in all measures. However, there is still a
need for improvement in prescrib-

Table 1. Heart Failure Quality Measures2,3
Measure

Description

Compliance*
MUSC

National

Evaluation of left
ventricular systolic
(LVS) function

Patients with heart failure must have documentation in the hospital record that
LVS function was evaluated before arrival, during hospitalization, or was
planned for after discharge. Reasons for no LVS assessment must be documented by a physician, physician assistant, or nurse practitioner.

100%

83%

ACEI or ARB
for (LVSD)

Patients with LVSD and without both ACEI and ARB contraindications must
have an ACEI or ARB prescribed at hospital discharge. Contraindications or
other reasons for not prescribing an ACEI or ARB must be documented by a
physician, physician assistant, or nurse practitioner.

91%

82%

Comprehensive
discharge
instructions

Written instructions or educational material must be provided to the patient or
care giver at discharge or during the hospital stay addressing all of the following: activity level, diet, discharge, medications, weight monitoring, and what to
do if symptoms worsen.

84%

60%

Smoking cessation
advice/counseling

Heart failure patients with a history of smoking cigarettes (defined as smoked
at any time during the past 12 months) must be given smoking cessation advice
or counseling during hospital stay.

96%

81%

* MUSC Compliance rates for July to September 2006; National compliance rates for July 2005 to June 2006
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Table 2. MUSC Tools for Compliance
Measure
Places for Documentation
ACEI or ARB for
LVSD

Adult Cardiovascular Discharge Orders
http://www.musc.edu/cce/ORDFRMS/pdf/cardiovascdc.pdf
Adult Cardiac Surgery Discharge Orders
http://www.musc.edu/cce/ORDFRMS/pdf/ctsurgdisch.pdf
Adult Cardiovascular Discharge Orders
http://www.musc.edu/cce/ORDFRMS/pdf/cardiovascdc.pdf

Discharge
instructions

Discharge Orders (Generic)
http://www.musc.edu/cce/ORDFRMS/pdf/dischgeneral.pdf
Congestive Failure Discharge Instructions
http://www.musc.edu/cce/ORDFRMS/pdf/chfdcinstruct.pdf
Adult Cardiac Surgery Discharge Orders
http://www.musc.edu/cce/ORDFRMS/pdf/ctsurgdisch.pdf
Inpatient History and Physical Form
(checkboxes on pages 6 and 7)
http://www.musc.edu/cce/ORDFRMS/pdf/longhp.pdf
Adult Cardiac Admission Orders
http://www.musc.edu/cce/ORDFRMS/pdf/cardiacadmit.pdf

Smoking cessation
advice/counseling

Adult Universal Admission Orders
http://www.musc.edu/cce/ORDFRMS/pdf/universaladmit.pdf
Cardiovascular Discharge Orders
http://www.musc.edu/cce/ORDFRMS/pdf/cardiovascdc.pdf
Discharge Orders (Generic) (checkbox on page 2)
http://www.musc.edu/cce/ORDFRMS/pdf/dischgeneral.pdf

ing ACEI or ARB at discharge
and discharge counseling. Typically the failures for the measures
are due to poor documentation of
the reason for not prescribing
ACEI or ARB or for not documenting counseling sessions. If
there is any contraindication for
therapy, it must be documented in
the medical record. This can be
documented on the discharge form
by marking “not prescribed
because” and listing the reason on
the discharge form. Therefore,
our efforts should focus on proper
documentation.
All health care providers have a
role in improving our performance
in these quality measures. This
will translate into improved patient outcomes.

The

Did You Know...
Manufacturers of pergolide
(Permax®) drug products, which
are used to treat Parkinson’s disease, voluntarily removed these
products from the market due to
the risk of serious damage to patients’ heart valves. Two recent
New England Journal of Medicine
studies confirm previous findings
associating pergolide with increased chance of regurgitation of
the mitral, tricuspid, and aortic
valves of the heart. Symptoms include shortness of breath, fatigue
and heart palpitations.
Novartis Pharmaceutical Coporation has voluntarily suspended
marketing of tesagerod
(Zelnorm®) at the request of FDA.
An increased risk of serious cardiovascular (CV) events may be
associated with the use of tegaserod. Novartis reported to FDA
the results of 29 short-term (1 to 3

MED•U•WAY
To Care For Patients
*** An MUSC Lecture Series***

The next MED•U•WAY
Program will focus on e-Care
Net, the MUSC Clinical Record.
The program will be held on
Thursday, May 17, 2007, at
12:00 PM, in 2 West
Amphitheater.
The featured speakers will be
David Soper, MD, Department
of Obstetrics and Gynecology,
Mark Daniels, Patient Support
S e r v i c e s- O C I O ; M a r ga r e t
Wheat, RPh, Pharmacy

Information Systems; and
Bonnie Foulois, RN, ClinDoc Project Manager.
The speakers will describe the
system plan and timeline, features
and functionality of the systems,
and how the systems will improve
patient care. Attendees will
receive 1 credit hour of continuing
education, and lunch is provided.
MED•U•WAY is sponsored by
the Pharmacy and Therapeutics
Committee.
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months) randomized, controlled
clinical trials. FDA has concluded, based on these data, that
for most patients the benefits of
this medication no longer outweigh the risks.
The analysis included more than
11,600 patients treated with
tesagerod and over 7000 patients
treated with placebo. The data
showed that the risk of serious CV
adverse events (eg, angina, heart
attacks, and strokes) associated
with use of tegaserod is higher
than with placebo treatment. Thirteen tegaserod-treated patients
(0.1%) had confirmed CV

ischemic events compared with
only 1 placebo-treated patient
(0.01%). FDA will work with
Novartis to allow access to
tegaserod as an investigational
drug for patients with no other
treatment options where the
benefits may outweigh the risks.
FDA has also indicated the possibility of considering limited reintroduction of tegaserod if a
population of patients can be
identified in which the benefits
of the drug outweigh the risks.
FDA announced that companies
must stop manufacturing and
distributing unapproved supposi-

tory drug products containing
trimethobenzamide hydrochloride.
These products are used to treat
nausea and vomiting in adults and
children. Drugs containing
trimethobenzamide in suppository
form lack evidence of effectiveness. These products have been
marketed under various names,
including Tigan®, Tebamide®, TGen®, Trimazide®, and
Trimethobenz®.
Detailed information regarding all
3 product removals can be found
on the FDA Center for Drug
E v a l u a t i o n We b p a g e a t
www.fda.gov/cder.

FORMULARY UPDATE FOR APRIL 2007
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. These items
were active on April 16, 2007.
Change in Formulary Status of
Gadolinium-based Intravenous
Contrast Agents
The formulary status of the gadolinium products was reviewed due
to the increasing incidence of
nephrogenic systemic fibrosis/
nephrogenic fibrosing dermopathy
(NSF/NFD).
NSF/NFD is a debilitating and
potentially fatal disease that may
be associated with the administration of gadolinium-based agents in
patients with moderate- to endstage renal disease. It is thought
that Magnevist® and gadobenate
(Multihance®) are less likely to
cause NSF/NFD compared with
gadodiamide (Omniscan®) due to
their thermodynamic and condition stability values, lack of excess chelates, and acid stability.

Added with Restriction:
Gadopentetate dimeglumine
(Magnevist®) is restricted to
prescribing in pediatric patients
only.
10- and 15-mL vials
Change in Restriction:
G a d o b e n a t e d i me g l u mi n e
(Multihance®) will be restricted
to prescribing in adult patients
only.
Deleted:
Gadodiamide (Omniscan®)
10-, 15-, and 20-mL vials; 15–
and 20 mL PFS vials
Guidelines Approved:
Guidelines for Antiemetic Use of
Chemotherapeutic-induced Nausea and Vomiting (CINV) have
been updated to reflect the
changes in current practice. The
guidelines will be available under Clinician Order Forms as
well as on the Department of
Pharmacy Web page.

MUSC Continuous Infusion
Guidelines for Pediatric Patients
have been updated to reflect the
National Patient Safety goal regarding standard concentrations.
The guidelines remove the use of
“Rule of 6” and apply a standard
concentration for all pediatric patients.
An on-line calculator has been
developed to assist health care
professionals in accurately determining standard concentrations
and infusion rates. Once a clinician has completed the on-line
form, it will be available to print
as a continuous infusion order
sheet.
An initial pilot project will take
place in the PICU. Therefore,
these guidelines are only to be
used in the PICU. The original
guidelines will stay current for the
other units in Children’s Hospital.
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Bioequivalence and Pharmaceutical Equivalence of Generic Drugs
By: Lauren Haney, PharmD Candidate
Brand name medications with
therapeutically equivalent formulations typically offer a less expensive option for patients. By
determining if a generic product is
therapeutically equivalent, the
best possible patient care will be
delivered through consistent medication regimens.1,4 Generic substitution for some prescription
drugs (eg, diltiazem extendedrelease capsules, etc) can be confusing.
For a generic formulation to be
deemed therapeutically equivalent
or AB-rated, the generic product
must meet strict criteria from the
Food and Drug Administration
(FDA).2,5 According to the Drug
Price Competition and Patent
Term Restoration Act of 1984,
data must be submitted from the
manufacturer to FDA proving bioequivalence of the generic formulation to the proprietary product.2,5
Bioequivalence is defined as the
absence of a significant difference
in the rate and the extent to which
the active ingredient of a medication reaches the site of action.3,5
Generic formulations undergo
pharmacokinetic and pharmacodynamic studies, comparative clinical trials, and in vitro studies.3-5
These tests ensure acceptable
safety, efficacy, and quality before
generic formulations are approved
by FDA.2-4
Pharmaceutical equivalents are
generic products that contain
equivalent amounts of the same
active ingredient compared with
the proprietary product.1,3 For ex-

ample, metformin hydrochloride,
manufactured by Watson Pharmaceuticals, Inc. is a pharmaceutical equivalent to Glucophage®.5
Therefore, generic
metformin hydrochloride is
therapeutically equivalent and
interchangeable with Glucophage®.5 Conversely, pharmaceutical alternatives that contain
the same therapeutic moiety but
not necessarily the same salt
form are not therapeutically
equivalent.1,3 For example, Cataflam® and Voltaren® contain diclofenac but Cataflam® contains
diclofenac potassium while Voltaren® contains diclofenac sodium.5 Cataflam® and Voltaren®
are not therapeutically equiva-

lent nor are these 2 formulations
interchangeable .5
Therapeutic Equivalence Evaluations, also known as the Orange
Book, is a resource of FDA.3,5
The Orange Book provides therapeutic equivalence ratings and is
the primary guide to determining
whether or not a generic product
is therapeutically equivalent to a
proprietary product.5,6 The Orange Book uses bioequivalence
codes, to compare each product to
the proprietary product, also know
as the reference listed drug
(RLD).3,5,6
If the first letter of the code is
“A,” it is used to designate prod-

FORMULARY UPDATE FOR MAY 2007
The Pharmacy and Therapeutics Committee recently approved the actions listed below.
These items will be active on
May 15, 2007.

Line Extensions:
Haemophilus influenzae type b
conjugate vaccine (ActHIB®)
0.5-mL intramuscular
injection

Added:
Hydroxyprogesterone caproate
was added to the formulary for
use in the prevention of preterm
delivery.
250-mg/mL extemporaneous
intramuscular injection

Sun-Dex® glucose beverage

Added with Restriction:
Ibandronate (Boniva IV) was
added to the formulary with prescribing restricted to postmenopausal women who fail or cannot
tolerate oral bisphosphonate
therapy.
1-mg/mL intravenous solution

Deletions:
Tegaserod (Zelnorm®)
2- and 6-mg tablets
Trimethobenzamide (Tigan®)
200-mg suppositories
Glutol™
Haemophilus influenzae type b
conjugate vaccine (HibTITER®)
0.5-mL intramuscular injection
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ucts that have demonstrated therapeutic equivalence. A first letter
of “B” signifies that bioequivalence has not been confirmed. The
second letter in the rating provides
additional information about the
product. Products for which there
are no known or suspected bioequivalence problems are rated as
AA, AN, AO, AP, or AT, depending on the dosage form. When
actual or potential bioequivalence
have been resolved with in vivo
and/or in vitro testing, this is denoted with an “AB” rating.2,5,6
Additionally, multiple RLDs may
be used for one drug entity. In
this case, FDA assigns a number
that is added to the end of the AB
code (eg, AB1, AB2, AB3). Products rated AB1 are bioequivalent
to each other, products rated AB2
are bioequivalent to each other,
and so forth.2,5,6
To further illustrate the bioequivalence codes used by the FDA, a
common patient care issue will be
explained. For example, diltiazem

hydrochloride, a calcium channel blocker, is marketed under
several trade names.7,8 Diltiazem hydrochloride is the active
ingredient in each of the products; however, not all of these
products are therapeutically
equivalent nor are all of these
formulations interchangeable.5,6
Table 1 contains the equivalents
for the diltiazem products that
can be found ion the Orange
Book.5,6
When multiple formulations are
available, it is important to note
that the formulation with a bioequivalence code is only interchangeable with the RLD.
Therefore, two generic formulations may not be therapeutically
equivalent to each other.5,6
Any drug available on the market before 1938 is considered an
unapproved drug and therefore,
“grandfathered” by FDA. Some
examples include digoxin, longacting guaifenesin products, and
carbinoxamine. Due to the status

of grandfathered products, there is
no FDA advice on the bioequivalence and substitutability of these
drugs.2,5
According to South Carolina state
law, “therapeutically equivalent”
means the same efficacy and
safety profile when administered
to an individual in the same dosage form.2,9 A pharmacist may
substitute a drug product of the
same dosage form and strength
that, in his/her professional judgment, is a therapeutically equivalent drug product.2,9 However, the
pharmacist is liable for substitution of drugs not recognized by
FDA as bioequivalent.2,9
If a patient is taking a proprietary
medication, it may be necessary to
find out if there is an AB-rated
generic formulation available. The
proper generic medication may be
dispensed in accordance with
FDA, South Carolina state law,
and the policies and procedures of
the Medical University of South
Carolina Medical Center.2,5,9
References available upon request

2,5

Table 1. Example of Diltiazem Therapeutic Equivalents
AB-Rating

Product

Therapeutic Equivalent

AB

*Cardizem (Biovail)

Diltiazem hydrochloride tablet
(Clonmel Healthcare; Ivax Pharms; Mylan, Teva)

AB2

*Dilacor XR (Watson)

Diltiazem extended release capsule (Andrx, Mylan, Torpharm)

AB3

*Cardizem CD 120, 180, 240, and 300 mg (Biovail)

Cartia XT (Andrx); Dilt-CD (Torpharm); Diltiazem extended
release capsule (Actavis Elizabeth, Biovail, Teva)

AB4

*Tiazac (Biovail)

Taztia XT (Andrx); Diltzac (Apotex Inc); Diltiazem extended
release capsule (KV Pharm)

BC

*Cardizem CD 360 mg (Biovail)

None

*Cardizem LA (Biovail)

None

*Cardizem injectable (Biovail)

Diltiazem injectable (Apotex Inc, Bedford, Hospira, Intl Medication, Mayne Pharma USA, Sicor Pharms, Taylor Pharma)

AP

*Indicates the RLD;
Brand (Trade) names are in italics
Specific manufacturers are listed in parentheses

